Add Row
Add Element
Glytain Logo
update
Glytain.com
update
Add Element
  • Home
  • Categories
    • Healthcare
    • Innovation
    • Digital
    • Marketing
    • Analysis
    • Insights
    • Trends
    • Empowerment
    • Providers
    • Tech News
    • Extra News
Add Row
Add Element
February 28.2025
2 Minutes Read

ViVE 2025: Bridging Technology and Human Connection in Healthcare Access

Panel discussion highlighting access to healthcare technology.

Connecting Technology to Care Access

During the recent ViVE 2025 conference in Nashville, industry leaders from community health centers and rural health systems emphasized the critical issues surrounding access to healthcare. With over 100 million Americans lacking consistent access to primary care due to provider shortages, innovative technology alone isn't a panacea. The narrative from the conference highlighted how understanding the unique needs of underprivileged communities is key to effective health interventions.

Innovating With Trust in Mind

"How do we keep community health centers from being left behind?" posed Johanna Liu, president of San Francisco Community Clinic Consortium. The survival of community health centers hinges not just on technology adoption but on fostering trust with the populations they serve. Providing services tailored to the community's specific socio-economic conditions—ranging from language barriers to food insecurity—can better enrich patient-provider interactions.

Building genuine relationships and understanding community context can improve healthcare delivery, as evidenced by Brian Haile, CEO of Neighborhood Health, who narrated actionable responses to patients' needs, such as offering food assistance.

AI’s Role in Enhancing Care

The topic of artificial intelligence also dominated discussions. Community health leaders expressed the potential of AI to streamline administrative processes and improve patient relationships. For instance, AI could facilitate translation services for non-English speaking patients and automate routine tasks, freeing providers to focus on more sensitive aspects of care.

As Ryan Thousand, interim CIO at Dahl Memorial Healthcare Association noted, many community providers have embraced existing technologies like telemedicine, which have proven to be essential in increasing patient reach, especially given the shortage of specialists in rural areas. Telehealth has transformed accessibility, ensuring that medical professionals can consult patients even from a distance.

A Call for Ground-Up Solutions

However, with these technological advancements comes the imperative of ensuring they align with community needs. Accessibility, especially in rural areas, requires a concerted effort to not only implement new technologies but to develop the infrastructure necessary for them to thrive. Rachelle Schultz, Winona Health President and CEO, encapsulated the sentiment when she stated, "We are people first. We must ensure technology doesn’t disrupt the valuable relationships built between patients and providers." This rallying cry underlines the need for balance—leveraging cutting-edge tech while nurturing the human bonds that are foundational to effective healthcare.

As rural providers continue to face barriers like budget constraints and pressure to innovate, the message from ViVE 2025 remains clear: Solutions must emerge from the grassroots, rooted in community engagement and trust, to truly elevate the standard of care across underserved regions.

Healthcare

Write A Comment

*
*
Related Posts All Posts

Explore Lipoprotein (a): Understanding Its Role in Cardiovascular Risk

Update Understanding Lipoprotein (a) and Cardiovascular Risks When it comes to heart health, many of us are familiar with cholesterol, but have you heard about lipoprotein (a)? Dr. Vlad Vasile from Mayo Clinic sheds light on this crucial lipid blood biomarker and its significant impact on cardiovascular risk in a recent discussion with Dr. Steve Kopecky.In 'Lipoprotein (a) Elevation: What Does it Do to Increase CV Risk and What to Know About Treatment', the discussion dives into lipoprotein (a) and its significant implications on cardiovascular health, prompting us to explore its effects and current treatment options. Lipoprotein (a), often abbreviated as Lp(a), is closely associated with LDL cholesterol or "bad cholesterol". According to Dr. Vasile, about one in five people have elevated levels of Lp(a), which can independently predict serious cardiovascular events like heart attacks and strokes, regardless of other lipid levels. This makes understanding and managing Lp(a) essential for overall heart health. The Genetic Component of Lipoprotein (a) What's particularly concerning is that Lp(a) has a strong genetic basis, meaning if one of your parents has elevated Lp(a), you might be at risk as well. This trait is a bit complex – our bodies produce two different isoforms of Lp(a), making it difficult to predict levels based solely on family history. Dr. Vasile emphasizes the importance of screening for Lp(a), encouraging not just individuals with elevated levels, but also their first-degree relatives to undergo testing. By catching elevated Lp(a) levels early, we can encourage proactive management and potentially reduce cardiovascular risks for multiple generations. Current and Future Treatments Currently, impactful treatments specifically targeting Lp(a) are limited, though some emerging therapies are showing promise in clinical trials. For now, lifestyle modifications like maintaining a Mediterranean diet, regular aerobic exercise, and possibly low-dose aspirin can help mitigate cardiovascular risk associated with Lp(a) elevation, even if they don’t directly lower Lp(a) levels. The outlook is hopeful, as there are several new drugs in the pipeline aimed at effectively lowering Lp(a). If you have elevated Lp(a) levels or cardiovascular concerns, stay informed about these developments and engage with your healthcare provider regarding your risk factors. As we continue to learn more about biomarkers like Lp(a), emphasizing the importance of awareness and proactive healthcare is crucial for heart disease prevention. Remember, your heart health matters!

FDA's Rejection of Capricor Cell Therapy Raises Questions in Healthcare Innovation

Update The FDA's Tough Decision on Capricor's Cell Therapy In a significant move for the realm of innovative healthcare solutions, the FDA has recently denied the approval of Capricor Therapeutics' experimental cell therapy, deramiocel, aimed at treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD). This decision highlights the ongoing complexities in developing treatments for rare muscle diseases, where the stakes are high and patient needs are urgent. Understanding Duchenne Muscular Dystrophy and Heart Issues Duchenne muscular dystrophy is a severe genetic disorder predominantly affecting young boys, characterized by progressive muscle degeneration. Among the challenges faced by these patients is the development of heart complications, which can lead to heart failure. Deramiocel was designed to address these specific cardiac issues by harnessing the healing capabilities of cardiac cells. However, the FDA raised concerns regarding the therapy's efficacy and safety, prompting the question of how innovative solutions can meet regulatory standards while addressing critical patient needs. The Path Ahead for Capricor and Patients Despite the setback, Capricor remains committed to exploring further options to facilitate a successful treatment pathway for its patients. Healthcare IT professionals and digital health innovators might see this as a crucial moment to push the boundaries of technology in assessing clinical outcomes. In many cases like this, patient advocacy can play a pivotal role in shaping the future of treatment possibilities. How This Decision Impacts Digital Health Solutions This decision emphasizes the necessity for robust data and innovative technological integration in the healthcare industry. Digital health entrepreneurs are presented with a unique opportunity to support research and development in rare disease areas, enhancing the potential for successful therapies in the future. The intersection of technology and healthcare will be essential in paving the way for better patient outcomes as the medical landscape evolves.

New Proposal for Research Overhead Cuts: What It Means for Innovation

Update Understanding the Importance of Research Funding In recent weeks, academic organizations have come together to address significant changes proposed by the Trump administration regarding research funding cuts. These changes threaten to severely limit the financial resources available for essential research activities. The response from the Joint Associations Group (JAG), representing a coalition of 10 academic entities, is both timely and critical. A Dual Approach: Innovative Funding Solutions JAG has finalized a counterproposal offering two distinct methods to secure funding for research overhead payments. The first option involves institutions providing a comprehensive breakdown of their indirect costs within project grants. This approach aims at transparency and can ensure that necessary expenses are effectively accounted for, making it easier for funding bodies to understand the actual costs associated with research. The second option proposes a simplified method, allowing institutions to receive a fixed percentage of a project’s total budget. This alternative is designed to streamline the process, making it less burdensome for researchers and their organizations. By offering these two pathways, JAG seeks not only to preserve funding but also to maintain the integrity of research operations across the country. Why Stakeholders Should Pay Attention The outcomes of these funding discussions hold weight beyond university walls—they impact patient care, innovative medical discoveries, and the advancement of science as a whole. Given that academic institutions often serve as incubators for groundbreaking research, finding solutions that secure sufficient funding is essential for the progression of healthcare and medicine. The Road Ahead: Will It Meet Resistance? The next steps involve gauging the acceptance of this counterproposal by lawmakers and the administration. Given the immense implications, it’s crucial for stakeholders—including researchers, policymakers, and the public—to remain engaged in this dialogue. Active participation in advocacy efforts could influence the decision-making process significantly, ensuring that essential research continues unimpeded. A Call for Advocacy As discussions regarding research funding unfold, it is important for everyone to stay informed and involved. Engaging with local representatives about the importance of continued investment in research could be a powerful step towards safeguarding the future of scientific innovation. Your voice matters—join in advocating for the funding that supports the research that ultimately benefits us all.

Add Row
Add Element
Glytain Logo
update
WorldPulse News
cropper
update

Glytain empowers healthcare professionals and businesses to navigate the evolving digital landscape, driving innovation and improving patient outcomes. 🚀

  • update
  • update
  • update
  • update
  • update
  • update
  • update
Add Element

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6
Add Element

+639220000000

AVAILABLE FROM 8AM - 5PM

City, State

, ,

Add Element

ABOUT US

At Glytain, we bridge the gap between healthcare and technology by delivering expert insights, cutting-edge trends, and in-depth analysis of digital health innovations. Our platform is designed for healthcare professionals, tech innovators, and forward-thinking businesses looking to stay ahead in the rapidly evolving healthcare landscape.

Add Element

© 2025 CompanyName All Rights Reserved. Address . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*